Here's how NATURE.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

NATURE . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Nature.com Make Money
  6. How Much Does Nature.com Make
  7. Keywords
  8. Topics
  9. Questions
  10. Schema
  11. Social Networks
  12. External Links
  13. Analytics And Tracking
  14. Libraries
  15. Hosting Providers
  16. CDN Services

We are analyzing https://www.nature.com/articles/386407a0.

Title:
Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists | Nature
Description:
Retinoic acid receptors (RAR), thyroid hormone receptors (TR), peroxisome proliferator activated receptors (PPARs) and the orphan receptor, LXR, bind preferentially to DNA as heterodimers with a common partner, retinoid X receptor (RXR), to regulate transcription1–6. We investigated whether RXR-selective agonists replicate the activity of ligands for several of these receptors? We demonstrate here that RXR-selective ligands (referred to as rexinoids) function as RXR heterodimer-selective agonists, activating RXR: PPARγ and RXR:LXR dimers but not RXR:RAR or RXR:TR heterodimers. Because PPARγ is a target for antidiabetic agents, we investigated whether RXR ligands could alter insulin and glucose signalling. In mouse models of non-insulin-dependent diabetes mellitus (NIDDM) and obesity, RXR agonists function as insulin sensitizers and can decrease hyperglycaemia, hypertriglyceridaemia and hyperinsulinaemia. This antidiabetic activity can be further enhanced by combination treatment with PPARγ agonists, such as thiazolidinediones. These data suggest that the RXR:PPARγ heterodimer is a single-function complex serving as a molecular target for treatment of insulin resistance. Activation of the RXR:PPARγ dimer with rexinoids may provide a new and effective treatment for NIDDM.
Website Age:
30 years and 10 months (reg. 1994-08-11).

Matching Content Categories {📚}

  • Science
  • Education
  • Telecommunications

Content Management System {📝}

What CMS is nature.com built with?

Custom-built

No common CMS systems were detected on Nature.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of nature.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Nature.com Make Money? {💸}


Display Ads {🎯}


The website utilizes display ads within its content to generate revenue. Check the next section for further revenue estimates.

Ads are managed by yourbow.com. Particular relationships are as follows:

Direct Advertisers (10)
google.com, pmc.com, doceree.com, yourbow.com, audienciad.com, onlinemediasolutions.com, advibe.media, aps.amazon.com, getmediamx.com, onomagic.com

Reseller Advertisers (38)
conversantmedia.com, rubiconproject.com, pubmatic.com, appnexus.com, openx.com, smartadserver.com, lijit.com, sharethrough.com, video.unrulymedia.com, google.com, yahoo.com, triplelift.com, onetag.com, sonobi.com, contextweb.com, 33across.com, indexexchange.com, media.net, themediagrid.com, adform.com, richaudience.com, sovrn.com, improvedigital.com, freewheel.tv, smaato.com, yieldmo.com, amxrtb.com, adyoulike.com, adpone.com, criteo.com, smilewanted.com, 152media.info, e-planning.net, smartyads.com, loopme.com, opera.com, mediafuse.com, betweendigital.com

How Much Does Nature.com Make? {💰}


Display Ads {🎯}

$63,100 per month
According to our algorithms, Nature.com's monthly online income from display advertising ranges from $42,042 to $115,616.

Keywords {🔍}

article, google, scholar, nature, cas, receptor, retinoid, access, receptors, rxr, ads, agonists, pparγ, cell, content, mice, insulin, retinoic, acid, ligand, cookies, hormone, center, usa, privacy, data, obese, thyroid, peroxisome, antidiabetic, signalling, diabetes, open, gene, evans, chem, science, california, research, diabetic, mukherjee, boehm, ligands, target, vitamin, response, umesono, nuclear, gamma, human,

Topics {✒️}

nature portfolio permissions reprints privacy policy cardiovascular research retinoid research advertising social media subscribe nature insulin-dependent diabetes mellitus nature 355 nature 358 nature 383 nature 345 nature 371 nature 372 nature 336 nature 386 nature single-function complex serving springerlink instant access rxr-selective agonists replicate permissions metabolic disorders induced rxr heterodimer-selective agonists personal data high affinity ligand retinoic acid receptors 9-cis retinoic acid promotes adipocyte differentiation ppar gamma diabetes gene encodes data protection data suggest leptin receptor gene insulin resistance privacy unique response pathways cognate response elements explore content subscription content uclear receptor lxrα european economic area regulate transcription1–6 institutional subscriptions read mouse obese gene alternative oxygen acceptor health science center human nutritional relevance suggested nutritional guidelines saad naunyn-schmiedeberg'

Questions {❓}

  • We investigated whether RXR-selective agonists replicate the activity of ligands for several of these receptors?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists
         description: Retinoic acid receptors (RAR), thyroid hormone receptors (TR), peroxisome proliferator activated receptors (PPARs) and the orphan receptor, LXR, bind preferentially to DNA as heterodimers with a common partner, retinoid X receptor (RXR), to regulate transcription1–6. We investigated whether RXR-selective agonists replicate the activity of ligands for several of these receptors? We demonstrate here that RXR-selective ligands (referred to as rexinoids) function as RXR heterodimer-selective agonists, activating RXR: PPARγ and RXR:LXR dimers but not RXR:RAR or RXR:TR heterodimers. Because PPARγ is a target for antidiabetic agents, we investigated whether RXR ligands could alter insulin and glucose signalling. In mouse models of non-insulin-dependent diabetes mellitus (NIDDM) and obesity, RXR agonists function as insulin sensitizers and can decrease hyperglycaemia, hypertriglyceridaemia and hyperinsulinaemia. This antidiabetic activity can be further enhanced by combination treatment with PPARγ agonists, such as thiazolidinediones. These data suggest that the RXR:PPARγ heterodimer is a single-function complex serving as a molecular target for treatment of insulin resistance. Activation of the RXR:PPARγ dimer with rexinoids may provide a new and effective treatment for NIDDM.
         datePublished:
         dateModified:
         pageStart:407
         pageEnd:410
         sameAs:https://doi.org/10.1038/386407a0
         keywords:
            Science
            Humanities and Social Sciences
            multidisciplinary
         image:
         isPartOf:
            name:Nature
            issn:
               1476-4687
               0028-0836
            volumeNumber:386
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Nature Publishing Group UK
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Ranjan Mukherjee
               affiliation:
                     name:Ligand Pharmaceuticals
                     address:
                        name:Departments of Cardiovascular Research, Ligand Pharmaceuticals, San Diego, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Peter J. A. Davies
               type:Person
               name:Diane L. Crombie
               affiliation:
                     name:Ligand Pharmaceuticals
                     address:
                        name:Departments of Retinoid Research, Ligand Pharmaceuticals, San Diego, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Eric D. Bischoff
               affiliation:
                     name:Ligand Pharmaceuticals
                     address:
                        name:Departments of Retinoid Research, Ligand Pharmaceuticals, San Diego, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Rosemary M. Cesario
               affiliation:
                     name:Ligand Pharmaceuticals
                     address:
                        name:Departments of Retinoid Research, Ligand Pharmaceuticals, San Diego, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Lily Jow
               affiliation:
                     name:Ligand Pharmaceuticals
                     address:
                        name:Departments of Cardiovascular Research, Ligand Pharmaceuticals, San Diego, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Lawrence G. Hamann
               affiliation:
                     name:Ligand Pharmaceuticals
                     address:
                        name:Endocrine Chemistry, Ligand Pharmaceuticals, San Diego, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Marcus F. Boehm
               affiliation:
                     name:Ligand Pharmaceuticals
                     address:
                        name:Departments of Retinoid Chemistry, Ligand Pharmaceuticals, San Diego, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Carl E. Mondon
               type:Person
               name:Alex M. Nadzan
               affiliation:
                     name:Ligand Pharmaceuticals
                     address:
                        name:Departments of Retinoid Chemistry, Ligand Pharmaceuticals, San Diego, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:James R. Paterniti
               affiliation:
                     name:Ligand Pharmaceuticals
                     address:
                        name:Departments of Cardiovascular Research, Ligand Pharmaceuticals, San Diego, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Richard A. Heyman
               affiliation:
                     name:Ligand Pharmaceuticals
                     address:
                        name:Departments of Retinoid Research, Ligand Pharmaceuticals, San Diego, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists
      description: Retinoic acid receptors (RAR), thyroid hormone receptors (TR), peroxisome proliferator activated receptors (PPARs) and the orphan receptor, LXR, bind preferentially to DNA as heterodimers with a common partner, retinoid X receptor (RXR), to regulate transcription1–6. We investigated whether RXR-selective agonists replicate the activity of ligands for several of these receptors? We demonstrate here that RXR-selective ligands (referred to as rexinoids) function as RXR heterodimer-selective agonists, activating RXR: PPARγ and RXR:LXR dimers but not RXR:RAR or RXR:TR heterodimers. Because PPARγ is a target for antidiabetic agents, we investigated whether RXR ligands could alter insulin and glucose signalling. In mouse models of non-insulin-dependent diabetes mellitus (NIDDM) and obesity, RXR agonists function as insulin sensitizers and can decrease hyperglycaemia, hypertriglyceridaemia and hyperinsulinaemia. This antidiabetic activity can be further enhanced by combination treatment with PPARγ agonists, such as thiazolidinediones. These data suggest that the RXR:PPARγ heterodimer is a single-function complex serving as a molecular target for treatment of insulin resistance. Activation of the RXR:PPARγ dimer with rexinoids may provide a new and effective treatment for NIDDM.
      datePublished:
      dateModified:
      pageStart:407
      pageEnd:410
      sameAs:https://doi.org/10.1038/386407a0
      keywords:
         Science
         Humanities and Social Sciences
         multidisciplinary
      image:
      isPartOf:
         name:Nature
         issn:
            1476-4687
            0028-0836
         volumeNumber:386
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Nature Publishing Group UK
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Ranjan Mukherjee
            affiliation:
                  name:Ligand Pharmaceuticals
                  address:
                     name:Departments of Cardiovascular Research, Ligand Pharmaceuticals, San Diego, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Peter J. A. Davies
            type:Person
            name:Diane L. Crombie
            affiliation:
                  name:Ligand Pharmaceuticals
                  address:
                     name:Departments of Retinoid Research, Ligand Pharmaceuticals, San Diego, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Eric D. Bischoff
            affiliation:
                  name:Ligand Pharmaceuticals
                  address:
                     name:Departments of Retinoid Research, Ligand Pharmaceuticals, San Diego, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Rosemary M. Cesario
            affiliation:
                  name:Ligand Pharmaceuticals
                  address:
                     name:Departments of Retinoid Research, Ligand Pharmaceuticals, San Diego, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Lily Jow
            affiliation:
                  name:Ligand Pharmaceuticals
                  address:
                     name:Departments of Cardiovascular Research, Ligand Pharmaceuticals, San Diego, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Lawrence G. Hamann
            affiliation:
                  name:Ligand Pharmaceuticals
                  address:
                     name:Endocrine Chemistry, Ligand Pharmaceuticals, San Diego, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Marcus F. Boehm
            affiliation:
                  name:Ligand Pharmaceuticals
                  address:
                     name:Departments of Retinoid Chemistry, Ligand Pharmaceuticals, San Diego, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Carl E. Mondon
            type:Person
            name:Alex M. Nadzan
            affiliation:
                  name:Ligand Pharmaceuticals
                  address:
                     name:Departments of Retinoid Chemistry, Ligand Pharmaceuticals, San Diego, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:James R. Paterniti
            affiliation:
                  name:Ligand Pharmaceuticals
                  address:
                     name:Departments of Cardiovascular Research, Ligand Pharmaceuticals, San Diego, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Richard A. Heyman
            affiliation:
                  name:Ligand Pharmaceuticals
                  address:
                     name:Departments of Retinoid Research, Ligand Pharmaceuticals, San Diego, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Nature
      issn:
         1476-4687
         0028-0836
      volumeNumber:386
Organization:
      name:Nature Publishing Group UK
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Ligand Pharmaceuticals
      address:
         name:Departments of Cardiovascular Research, Ligand Pharmaceuticals, San Diego, USA
         type:PostalAddress
      name:Ligand Pharmaceuticals
      address:
         name:Departments of Retinoid Research, Ligand Pharmaceuticals, San Diego, USA
         type:PostalAddress
      name:Ligand Pharmaceuticals
      address:
         name:Departments of Retinoid Research, Ligand Pharmaceuticals, San Diego, USA
         type:PostalAddress
      name:Ligand Pharmaceuticals
      address:
         name:Departments of Retinoid Research, Ligand Pharmaceuticals, San Diego, USA
         type:PostalAddress
      name:Ligand Pharmaceuticals
      address:
         name:Departments of Cardiovascular Research, Ligand Pharmaceuticals, San Diego, USA
         type:PostalAddress
      name:Ligand Pharmaceuticals
      address:
         name:Endocrine Chemistry, Ligand Pharmaceuticals, San Diego, USA
         type:PostalAddress
      name:Ligand Pharmaceuticals
      address:
         name:Departments of Retinoid Chemistry, Ligand Pharmaceuticals, San Diego, USA
         type:PostalAddress
      name:Ligand Pharmaceuticals
      address:
         name:Departments of Retinoid Chemistry, Ligand Pharmaceuticals, San Diego, USA
         type:PostalAddress
      name:Ligand Pharmaceuticals
      address:
         name:Departments of Cardiovascular Research, Ligand Pharmaceuticals, San Diego, USA
         type:PostalAddress
      name:Ligand Pharmaceuticals
      address:
         name:Departments of Retinoid Research, Ligand Pharmaceuticals, San Diego, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Ranjan Mukherjee
      affiliation:
            name:Ligand Pharmaceuticals
            address:
               name:Departments of Cardiovascular Research, Ligand Pharmaceuticals, San Diego, USA
               type:PostalAddress
            type:Organization
      name:Peter J. A. Davies
      name:Diane L. Crombie
      affiliation:
            name:Ligand Pharmaceuticals
            address:
               name:Departments of Retinoid Research, Ligand Pharmaceuticals, San Diego, USA
               type:PostalAddress
            type:Organization
      name:Eric D. Bischoff
      affiliation:
            name:Ligand Pharmaceuticals
            address:
               name:Departments of Retinoid Research, Ligand Pharmaceuticals, San Diego, USA
               type:PostalAddress
            type:Organization
      name:Rosemary M. Cesario
      affiliation:
            name:Ligand Pharmaceuticals
            address:
               name:Departments of Retinoid Research, Ligand Pharmaceuticals, San Diego, USA
               type:PostalAddress
            type:Organization
      name:Lily Jow
      affiliation:
            name:Ligand Pharmaceuticals
            address:
               name:Departments of Cardiovascular Research, Ligand Pharmaceuticals, San Diego, USA
               type:PostalAddress
            type:Organization
      name:Lawrence G. Hamann
      affiliation:
            name:Ligand Pharmaceuticals
            address:
               name:Endocrine Chemistry, Ligand Pharmaceuticals, San Diego, USA
               type:PostalAddress
            type:Organization
      name:Marcus F. Boehm
      affiliation:
            name:Ligand Pharmaceuticals
            address:
               name:Departments of Retinoid Chemistry, Ligand Pharmaceuticals, San Diego, USA
               type:PostalAddress
            type:Organization
      name:Carl E. Mondon
      name:Alex M. Nadzan
      affiliation:
            name:Ligand Pharmaceuticals
            address:
               name:Departments of Retinoid Chemistry, Ligand Pharmaceuticals, San Diego, USA
               type:PostalAddress
            type:Organization
      name:James R. Paterniti
      affiliation:
            name:Ligand Pharmaceuticals
            address:
               name:Departments of Cardiovascular Research, Ligand Pharmaceuticals, San Diego, USA
               type:PostalAddress
            type:Organization
      name:Richard A. Heyman
      affiliation:
            name:Ligand Pharmaceuticals
            address:
               name:Departments of Retinoid Research, Ligand Pharmaceuticals, San Diego, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Departments of Cardiovascular Research, Ligand Pharmaceuticals, San Diego, USA
      name:Departments of Retinoid Research, Ligand Pharmaceuticals, San Diego, USA
      name:Departments of Retinoid Research, Ligand Pharmaceuticals, San Diego, USA
      name:Departments of Retinoid Research, Ligand Pharmaceuticals, San Diego, USA
      name:Departments of Cardiovascular Research, Ligand Pharmaceuticals, San Diego, USA
      name:Endocrine Chemistry, Ligand Pharmaceuticals, San Diego, USA
      name:Departments of Retinoid Chemistry, Ligand Pharmaceuticals, San Diego, USA
      name:Departments of Retinoid Chemistry, Ligand Pharmaceuticals, San Diego, USA
      name:Departments of Cardiovascular Research, Ligand Pharmaceuticals, San Diego, USA
      name:Departments of Retinoid Research, Ligand Pharmaceuticals, San Diego, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(103)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Prism.js
  • Zoom.js

Emails and Hosting {✉️}

Mail Servers:

  • mxa-002c5801.gslb.pphosted.com
  • mxb-002c5801.gslb.pphosted.com

Name Servers:

  • pdns1.ultradns.net
  • pdns2.ultradns.net
  • pdns3.ultradns.org
  • pdns4.ultradns.org
  • pdns5.ultradns.info
  • pdns6.ultradns.co.uk

CDN Services {📦}

  • Crossref

4.86s.